Skip to main content
editorial
. 2021 Feb;69(2):207–208. doi: 10.4103/ijo.IJO_150_21

Figure 1.

Figure 1

Innovator, biosimilar, biosuperior and novel medicine – the difference (adapted from https://www.drugdiscoverytrends.com/nextgeneration- of-biosimilars-and-biobetters-challenges-and-opportunities)